Skip to main content
Top
Published in: Current Pain and Headache Reports 5/2011

01-10-2011

Treatment of Chronic Migraine Headache with OnabotulinumtoxinA

Author: Robert Gerwin

Published in: Current Pain and Headache Reports | Issue 5/2011

Login to get access

Abstract

Chronic migraine headache remains an exceedingly difficult entity to manage. Treatment of chronic migraine headache with onabotulinumtoxinA has recently been shown to be effective in reducing the severity and frequency of chronic migraine headache, in the PREEMPT trials, a landmark achievement. However, the studies use a primarily fixed dose and site approach to treatment, allowing some individualized injections. However, the authors do not address the issue of myofascial trigger points as potential triggers of migraine that could be inactivated using onabotulinumtoxinA, despite several studies that support the role of myofascial trigger points in initiating some migraine headaches.
Literature
1.
go back to reference Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin A. Neurotoxicity. 2005;26:785–93.CrossRef Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin A. Neurotoxicity. 2005;26:785–93.CrossRef
2.
go back to reference Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin A: implications of migraine therapy. Headache. 2004;44:35–43.PubMedCrossRef Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin A: implications of migraine therapy. Headache. 2004;44:35–43.PubMedCrossRef
3.
go back to reference Meng J, Wang J, Lawrence G, Dolly GO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons to inhibition by botulinum toxins reflects their antinociceptive potential. J Cell Sci. 2007;120:2864–74.PubMedCrossRef Meng J, Wang J, Lawrence G, Dolly GO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons to inhibition by botulinum toxins reflects their antinociceptive potential. J Cell Sci. 2007;120:2864–74.PubMedCrossRef
4.
go back to reference Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.PubMedCrossRef Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.PubMedCrossRef
5.
go back to reference Diener HC, Dodick DW, Aurora SK, Turkel CC, DrGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.PubMedCrossRef Diener HC, Dodick DW, Aurora SK, Turkel CC, DrGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.PubMedCrossRef
6.
go back to reference Dodick DW, Turkel CC, DeGryse RE, Aurora SH, Silberstein SD, Lipton RB, et al. OnaboutlinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–36.PubMedCrossRef Dodick DW, Turkel CC, DeGryse RE, Aurora SH, Silberstein SD, Lipton RB, et al. OnaboutlinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–36.PubMedCrossRef
7.
go back to reference Tflet-Hanson P, Lous I, Olesen J. Prevalence and significance of muscle tenderness during common migraine headache. Headache. 1981;21:49–54.CrossRef Tflet-Hanson P, Lous I, Olesen J. Prevalence and significance of muscle tenderness during common migraine headache. Headache. 1981;21:49–54.CrossRef
8.
go back to reference Giamberardino MA, Tafuri E, Savini A, Fabrizio A, Affaitati G, Lerza R, et al. Contribution of myofascial trigger points to migraine symptoms. J Pain. 2007;8:869–78.PubMedCrossRef Giamberardino MA, Tafuri E, Savini A, Fabrizio A, Affaitati G, Lerza R, et al. Contribution of myofascial trigger points to migraine symptoms. J Pain. 2007;8:869–78.PubMedCrossRef
9.
go back to reference Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406–18.PubMedCrossRef Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406–18.PubMedCrossRef
Metadata
Title
Treatment of Chronic Migraine Headache with OnabotulinumtoxinA
Author
Robert Gerwin
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Pain and Headache Reports / Issue 5/2011
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-011-0202-6

Other articles of this Issue 5/2011

Current Pain and Headache Reports 5/2011 Go to the issue